Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292664 · ClinicalTrials.gov registry record · Phase 1
Venetoclax Basket Trial for High Risk Hematologic Malignancies
A Phase 1 study of Therapy-Related Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia, in Relapse, sponsored by Andrew E. Place, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT05292664 is a Phase 1 study of Therapy-Related Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia, in Relapse that is actively recruiting participants, run by Andrew E. Place, MD. The registered enrollment target is 30 participants, below the 82-participant average among 4 other Therapy-Related Myelodysplastic Syndrome trials with a reported enrollment target (63% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT05292664, a Phase 1 study of Therapy-Related Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia, in Relapse, is actively recruiting participants, sponsored by Andrew E. Place, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). The names of the study drugs involved in this study are below. Please note this is a list for the study as a whole, participants will receive drugs according to disease cohort. * Venetoclax * Azacitidine * Cytarabine * Methotrexate * Hydrocortisone * Leucovorin * Dexamethasone * Vincristine * Doxorubicin * Dexrazoxane * Calaspargase pegol * Hydrocortisone
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Cytarabine
- DRUG Methotrexate
- DRUG Hydrocortisone
Study Locations (5)
California
- University of California San Francisco-Benioff Children's Hospital - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta at Arthur M. Blank Hospital - Atlanta
Illinois
- Ann & Robert H Lurie Children's Hospital of Chicago - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-03-29 |
| Est. Completion | 2030-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05292664
The ClinicalTrials.gov registry entry for NCT05292664 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 4 other Therapy-Related Myelodysplastic Syndrome trials with a reported enrollment target (63% lower). The listed sponsor is Andrew E. Place, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Therapy-Related Myelodysplastic Syndrome appearing as the primary indexed condition, and to 5 interventions - of which Venetoclax is the first listed.
NCT05292664 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT05292664 about?
NCT05292664 is a clinical study titled "Venetoclax Basket Trial for High Risk Hematologic Malignancies". This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia...
What is the current status of trial NCT05292664?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-03-29. Estimated completion is 2030-07-02.
What conditions does trial NCT05292664 study?
This clinical trial studies the following conditions: Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Myelodysplastic Syndromes, Previously Treated, Acute Leukemia of Ambiguous Lineage in Relapse, Myelodysplastic Syndromes, de Novo.
What interventions are being tested in trial NCT05292664?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Cytarabine (DRUG), Methotrexate (DRUG), Hydrocortisone (DRUG).
Who is sponsoring clinical trial NCT05292664?
This trial is sponsored by Andrew E. Place, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05292664 being conducted?
This trial has 5 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Therapy-Related Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 3
-
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Therapy-Related Myelodysplastic Syndrome
All registered trials for this condition
Acute Lymphoblastic Leukemia, in Relapse
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.